Targets › SLC5A1
3 programs from 3 companies in 8 trials: 4 Phase 3, 3 Phase 2, 1 Phase 1; Metabolic and endocrine, Cardiovascular, Gastroenterology; next expected readout Jan 2027.
Electrogenic Na(+)-coupled sugar symporter that actively transports D-glucose or D-galactose at the plasma membrane, with a Na(+) to sugar coupling ratio of 2:1. Transporter activity is driven by a transmembrane Na(+) electrochemical gradient set by the Na(+)/K(+) pump. (UniProt, P13866)
Open in Phaseline: the race on SLC5A1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Colgate Palmolive | 0.45% SnF HW with NaF (1450 F) Stannous fluoride with sodium fluoride for topical fluoride delivery and antimicrobial act | SLC5A1 | Phase 3 | Plaque | Jan 2027 |
| Lexicon Pharmaceuticals | Sotagliflozin Sodium/glucose cotransporter 1 inhibitor; Sodium/glucose cotransporter 2 inhibitor | SLC5A1, SLC5A2 | Phase 3 | Obstructive Cardiomyopathy, Hypertrophic; Diabetic Nephropathies; Cardiovascular Diseases; Type 1 Diabetes | Jan 2027 |
| Vogenx | Mizagliflozin 5 mg SGLT1 inhibitor | SLC5A1 | Phase 2 | Postbariatric Hypoglycemia | Oct 2027 |
Type 1 Diabetes (2) Postbariatric Hypoglycemia (2) Obstructive Cardiomyopathy, Hypertrophic (1) Diabetic Nephropathies (1) Cardiovascular Diseases (1) Plaque (1)
small molecule (3)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.